🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12145925

Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treat

The Regents of the University of California · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12138263

Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof

Relay Therapeutics, Inc. · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12133849

Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting

Actinium Phamaceuticals, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128048

Combination therapies using PRMT5 inhibitors for the treatment of cancer

Mirati Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12129263

Kinase inhibitors and uses thereof

DENALI THERAPEUTICS INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12129262

CDK inhibitors and their use as pharmaceuticals

Prelude Therapeutics, Incorporated · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128015

APE/REF1 inhibitors for the treatment of cancer

The Regents of the University of California · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121522

Methods of treating cancer with an mTOR inhibitor

Revolution Medicines, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121524

DNA-PK inhibitors

Vertex Pharmaceuticals Incorporated · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12122773

Crystalline hydrate of a JAK inhibitor compound

Theravance Biopharma R&D IP, LLC · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12123001

Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121540

CBL inhibitors and compositions for use in adoptive cell therapy

NURIX THERAPEUTICS, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116354

RIP1 inhibitory compounds and methods for making and using the same

Rigel Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115163

Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor

IDEAYA Biosciences, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116343

Inhibitors of APOL1 and methods of using same

Vertex Pharmaceuticals Incorporated · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115156

Compositions of CXCR4 inhibitors and methods of preparation and use

X4 Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116346

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12103907

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

Arcus Biosciences, Inc. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097213

Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation thera

The Board of Regents of the University of Texas System · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097262

mTORC1 inhibitors

The Regents of the University of California · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097210

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

Corcept Therapeutics Incorporated · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097199

Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084447

SHP2 phosphatase inhibitors and methods of use thereof

Relay Therapeutics, Inc. · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084438

GCN2 inhibitors and uses thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted